September 20 , 2007 »»» BioVex Appoints Dr. Leonard Post to Board of Directors BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Leonard Post, age 55, to its Board of Directors. Dr. Post is currently CSO of LEAD Therapeutics, a small molecule drug discovery company. Previously, he served as Senior Vice President of Research and Development for Onyx Pharmaceuticals from 2000 to 2006. In this role, he was responsible for the co-development of Nexavar through to FDA approval for renal cancer, and until 2004 also led Onyx's oncolytic virus clinical program. Prior to joining Onyx, Dr. Post was VP Discovery Research at Parke Davis. Dr. Post holds a Ph.D. in Biochemistry from the University of Wisconsin and a BS in Chemistry from the University of Michigan. Philip Astley-Sparke, President & CEO of BioVex Inc, said: "Len brings to the Board considerable experience in progressing oncology products through development to regulatory approval. His specific and in depth knowledge of oncolytic products from both his work at Onyx and from his post doctoral fellowship in virology at the University of Chicago will prove valuable as we move OncoVEX GM-CSF through pivotal trials." About BioVex BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease. BioVex's lead cancer program, OncoVEX GM-CSF, is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX GM-CSF is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging, demonstrating OncoVEX GM-CSF has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX GM-CSF as stand alone therapy in patients with stage IIIc and stage IV metastatic disease. The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX HSV2 is scheduled to initiate later this year. For more information visit the company's website at www.biovex.com. Back to NEWS HEADLINES